- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
More ▼
Key statistics
On Friday, Supernus Pharmaceuticals Inc (SUPN:NMQ) closed at 29.40, 33.70% above the 52 week low of 21.99 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.67 |
---|---|
High | 29.53 |
Low | 28.67 |
Bid | 18.44 |
Offer | 40.00 |
Previous close | 28.87 |
Average volume | 407.39k |
---|---|
Shares outstanding | 54.73m |
Free float | 51.93m |
P/E (TTM) | 1,159.76 |
Market cap | 1.61bn USD |
EPS (TTM) | -0.0152 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼